BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20693500)

  • 1. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
    Tan X; Sidell N; Mancini A; Huang RP; Shenming Wang ; Horowitz IR; Liotta DC; Taylor RN; Wieser F
    Reprod Sci; 2010 Oct; 17(10):931-40. PubMed ID: 20693500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin analog EF24 induces apoptosis via ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
    He G; Feng C; Vinothkumar R; Chen W; Dai X; Chen X; Ye Q; Qiu C; Zhou H; Wang Y; Liang G; Xie Y; Wu W
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1151-1161. PubMed ID: 27787644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions.
    Premanand C; Rema M; Sameer MZ; Sujatha M; Balasubramanyam M
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2179-84. PubMed ID: 16639030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression.
    Selvendiran K; Tong L; Vishwanath S; Bratasz A; Trigg NJ; Kutala VK; Hideg K; Kuppusamy P
    J Biol Chem; 2007 Sep; 282(39):28609-28618. PubMed ID: 17684018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2.
    Zhang P; Bai H; Liu G; Wang H; Chen F; Zhang B; Zeng P; Wu C; Peng C; Huang C; Song Y; Song E
    Toxicol Lett; 2015 May; 234(3):151-61. PubMed ID: 25725129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.
    Subramaniam D; May R; Sureban SM; Lee KB; George R; Kuppusamy P; Ramanujam RP; Hideg K; Dieckgraefe BK; Houchen CW; Anant S
    Cancer Res; 2008 Mar; 68(6):1962-9. PubMed ID: 18339878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo.
    Yang CH; Yue J; Sims M; Pfeffer LM
    PLoS One; 2013; 8(8):e71130. PubMed ID: 23940701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro].
    Deng G; Yu JH; Ye ZQ; Hu ZQ
    Zhonghua Nan Ke Xue; 2008 Feb; 14(2):116-21. PubMed ID: 18390174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
    Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P
    Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells.
    He Y; Li W; Zhang J; Yang Y; Qian Y; Zhou D
    Curr Cancer Drug Targets; 2021; 21(7):608-618. PubMed ID: 33655859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.
    Liu H; Liang Y; Wang L; Tian L; Song R; Han T; Pan S; Liu L
    PLoS One; 2012; 7(10):e48075. PubMed ID: 23118928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
    Thomas SL; Zhao J; Li Z; Lou B; Du Y; Purcell J; Snyder JP; Khuri FR; Liotta D; Fu H
    Biochem Pharmacol; 2010 Nov; 80(9):1309-16. PubMed ID: 20615389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma.
    Yin DL; Liang YJ; Zheng TS; Song RP; Wang JB; Sun BS; Pan SH; Qu LD; Liu JR; Jiang HC; Liu LX
    Sci Rep; 2016 Aug; 6():32167. PubMed ID: 27571770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines.
    Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR.
    Chen A; Xu J
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G447-56. PubMed ID: 15486348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EF24 induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in gastric cancer cells.
    Zou P; Xia Y; Chen W; Chen X; Ying S; Feng Z; Chen T; Ye Q; Wang Z; Qiu C; Yang S; Liang G
    Oncotarget; 2016 Apr; 7(14):18050-64. PubMed ID: 26919110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
    Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G
    J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EF24 induces ferroptosis in osteosarcoma cells through HMOX1.
    Lin H; Chen X; Zhang C; Yang T; Deng Z; Song Y; Huang L; Li F; Li Q; Lin S; Jin D
    Biomed Pharmacother; 2021 Apr; 136():111202. PubMed ID: 33453607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
    Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.